Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2023-06-19 Major Shareholding Noti…
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled "FORM 8.3 - Dechra Pharmaceuticals plc" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is a Public Opening Position Disclosure or Dealing Disclosure made by a person holding 1% or more interests in relevant securities during a takeover situation. This type of disclosure relates to insider trading or significant ownership changes during a M&A event, which aligns closely with the scope of M&A Activity (TAR) or Director's Dealing (DIRS), but Form 8.3 is specifically mandated by the Takeover Code regarding parties involved in an offer. Since the definitions provided do not have a specific code for Takeover Code Disclosures (like Form 8.3), the closest fit among the options that deals with transactions by significant parties during a takeover/merger context is M&A Activity (TAR). However, Form 8.3 is fundamentally an insider/significant shareholder transaction disclosure related to a takeover. Given the options, 'Director's Dealing' (DIRS) covers personal share transactions by executives, and while this is by an investment manager (Millennium International Management LP), it is directly tied to a takeover situation involving Dechra Pharmaceuticals plc. Since the document details positions and dealings of a major shareholder/stakeholder during an ongoing offer, it is most accurately classified under M&A Activity (TAR) as it is a direct consequence of the takeover process governed by the Takeover Code.
2023-06-19 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is clearly identified by the header 'RNS Number : 1397D' and contains the standard structure of a TR-1 form, which is used for 'notification of major holdings'. This type of filing reports changes in significant share ownership thresholds. The definition for 'Major Shareholding Notification' is 'MRQ'. Although the content relates to insider/major shareholder activity, the specific regulatory form TR-1 corresponds directly to the Major Shareholding Notification category (MRQ) rather than Director's Dealing (DIRS) which is for personal transactions by directors, or Regulatory Filings (RNS) which is a fallback. The document is a specific regulatory disclosure, not a general announcement of a report.
2023-06-19 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is explicitly labeled as 'TR-1: Standard form for notification of major holdings' and contains an 'RNS Number'. This form is used to report changes in significant share ownership thresholds, which aligns directly with the definition of a Major Shareholding Notification. The presence of 'RNS Number' and the structure of the filing confirm it is a regulatory disclosure related to share ownership changes, fitting the 'MRQ' category (Major Shareholding Notification). Although it is distributed via RNS, the content is specific enough to warrant the MRQ classification over the general RNS fallback.
2023-06-16 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled 'FORM 8.3 - Dechra Pharmaceuticals plc' and references 'Rule 8.3 of the Takeover Code (the “Code”)'. This form is a 'PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE'. This type of disclosure relates to insider/significant shareholder activity during a takeover or merger situation. While it involves share dealings, it is a specific regulatory filing related to M&A activity under the Takeover Code, rather than a general Director's Dealing (DIRS) or a general Transaction in Own Shares (POS). Given the context of a takeover code disclosure, it is most closely related to M&A Activity (TAR) or potentially a specific Regulatory Filing (RNS). However, since the definitions do not explicitly list 'Takeover Code Disclosure Form 8.3', and it details dealings by a significant shareholder during a potential offer, it falls under the scope of M&A Activity (TAR) or the general Regulatory Filings (RNS). Since the document details specific dealings and positions related to an offer scenario, and 'TAR' covers 'merger proposals or takeover bids', this is the most specific fit among the provided options, although RNS is a strong fallback. Given the highly specific nature of the form related to a takeover, I will classify it as M&A Activity (TAR).
2023-06-16 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is explicitly labeled as 'TR-1: Standard form for notification of major holdings' and contains an 'RNS Number'. This form is used to report changes in significant share ownership thresholds, which directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content is a mandatory regulatory disclosure regarding share ownership changes, making MRQ the most precise classification over the general RNS fallback.
2023-06-16 English
Directorate Change
Board/Management Information Classification · 99% confidence The document is a formal announcement disseminated via RNS (Regulatory Information Service) with an RNS Number (0312D) and includes standard disclaimers related to the London Stock Exchange and Market Abuse Regulation (MAR). The core content announces a 'Directorate Change'—specifically, the resignation of a Non-Executive Director (Ishbel Macpherson). This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition for Board/Management Information (MANG). Although it is distributed via RNS, the specific subject matter is MANG, which takes precedence over the general regulatory filing category.
2023-06-16 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.